-
November 1, 2000PREVIEW
For many aches and pains associated with rheumatic diseases, NSAIDs reach levels in target tissues after topical administration similar to those achieved with oral administration. In several...
-
September 1, 2000PREVIEW
The tumor necrosis factor (TNF) inhibitor etanercept (Enbrel—Immunex, Wyeth-Ayerst) is proving a useful addition to available systemic therapies for psoriasis and psoriatic arthritis.
-
June 1, 2000PREVIEW
Regardless of how selective the new COX-2 inhibitors may be in the GI tract, they should be used with caution—or not at all—in patients with chronic renal failure, severe cardiac...
-
May 1, 2000PREVIEW
If barriers of cost, access, and reimbursement can be overcome, the new tissue necrosis factor (TNF) blockers hold much promise for treatment of juvenile rheumatoid arthritis.
-
March 1, 2000PREVIEW
Patients with advanced cases of rheumatoid arthritis must sometimes choose between etanercept (Enbrel—Wyeth-Ayerst, Immunex) and infliximab (Remicade—Centocor). Despite a lack of...
Pages
